title: Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
abstract: Interferon-based regimens with first-generation protease inhibitors have a limited efficacy and an unfavorable safety profile. Combination therapies with two or more second-generation direct-acting antivirals plus/minus ribavirin revolutionized treatment strategies in patients chronically infected with hepatitis C virus. In this rapidly evolving era, patients in the transplant setting benefit from interferon-free treatment regimens. Scientific societies can barely keep up with this development, making it necessary to update the clinical guidelines by the American and European Associations for the Study of Liver Diseases within short periods. This review presents and discusses the currently available data of the use of interferon-free treatment in the setting of liver transplantation. However, costs, different reimbursement strategies, and health-care options cannot be answered by guidelines and recommendations from scientific societies. Further investigator-initiated trials are needed to individualize treatment concepts.
authors: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
authors: Sandra
authors: S
authors: Beinhardt
authors: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
authors: Markus
authors: M
authors: Peck-Radosavljevic
authors: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
authors: Harald
authors: H
authors: Hofer
authors: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
authors: Peter
authors: P
authors: Ferenci
mesh_terms: D015081:2-Naphthylamine; D000813:Anilides / Q000008:administration & dosage; D000998:Antiviral Agents / Q000008:administration & dosage*; D002219:Carbamates / Q000008:administration & dosage; D002780:Cholestasis, Intrahepatic / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005355:Fibrosis; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007372:Interferons; D047029:Lactams, Macrocyclic; D008103:Liver Cirrhosis / Q000601:surgery*; D016031:Liver Transplantation; D047028:Macrocyclic Compounds / Q000008:administration & dosage; D011392:Proline / Q000031:analogs & derivatives; D012254:Ribavirin / Q000008:administration & dosage; D000069616:Simeprevir / Q000008:administration & dosage; D000069474:Sofosbuvir / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D014633:Valine
chemical_list: D000813:Anilides; D000998:Antiviral Agents; D002219:Carbamates; D003521:Cyclopropanes; D007166:Immunosuppressive Agents; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds; D013449:Sulfonamides; C586094:ombitasvir; D012254:Ribavirin; D014498:Uracil; D007372:Interferons; D011392:Proline; D000069616:Simeprevir; D015081:2-Naphthylamine; C588260:dasabuvir; D014633:Valine; C585405:paritaprevir; D000069474:Sofosbuvir
keywords: HCV recurrence; cirrhosis - compensated; decompensated; direct-acting antivirals; fibrosing cholestatic hepatitis; liver transplantation; recommendations; treatment guidelines